New Drug-Resistant TB Treatment Guidelines
In November 2019, DTBE released new practice guidelines for the Treatment of Drug-Resistant Tuberculosis. The guidelines were published in the American Journal of Respiratory and Critical Care Medicine and developed by CDC, the American Thoracic Society (ATS), the Infectious Diseases Society of America (IDSA), and the European Respiratory Society.
The new guidelines provide recommendations for treating multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB), as well as isoniazid-resistant TB. The recommendations prioritize orally-administered medications to make treatment more tolerable and improve patient outcomes, and provide guidance on the choice and number of drugs to use during treatment. Importantly, the recommendations address treatment of contacts to drug-resistant TB cases to prevent future drug-resistant TB disease. Recommendations also cover treatment length, the role of surgery, practices for treating special populations, and monitoring treatment.
CDC offers resources to help raise awareness of drug-resistant TB, including personal stories of MDR TB survivors like Nauman and Tenzin, infographics, and the latest U.S. drug-resistant TB data.
.png)
No hay comentarios:
Publicar un comentario